The GLP is committed to full transparency. Download and review our 2019 Annual Report

Canada: In search of genomic incentives

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

In a renewed quest for medical breakthroughs, the Canadian government recently committed $67.5-million for research into “personalized medicine.” This bold initiative promises faster, smarter and cheaper drug development by uncovering new targets, identifying patients likely to benefit from experimental therapies, and using molecular markers of disease to predict drug response.

Yet, personalized medicine follows on decades of efforts at plying molecular genetics toward drug development. To be sure, these approaches have borne fruit. But the process of developing cures remains painfully slow, error prone and costly. Despite steady increases in industry and public investment in research, the number of new drugs approved each year continues to decline.

Personalized medicine may very well fix a science that seems to be failing drug development. But perhaps we should be asking how drug development is failing science.

View the original article here: In search of genomic incentives

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend